We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

The company’s primary product is efruxifermin (EFX), which treats MASH and is undergoing phase 3 of clinical trials. Efruxifermin (EFX) is an analog of fibroblast growth factor 21, an endogenously ...

Survodutide also achieved ALT reduction of 65% after 1 year. Second, the FGF21 injectables (Pegozafermin and Efruxifermin), which in my view lag behind the GLP-1 class due to weaker ALT reduction ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...

Akero’s lead product candidate, Efruxifermin (EFX), is an Fc-FGF21 fusion protein engineered to mimic the balanced biological activity of native fibroblast growth factor 21 (FGF21). FGF21 is an ...